Accelerated DNA methylation age plays a role in the impact of cardiovascular risk factors on the human heart.
Advanced electrocardiography
Aging
DNA methylation age
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
18 10 2023
18 10 2023
Historique:
received:
27
06
2023
accepted:
29
09
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand the extent to which DNAm AgeAccel relates to cardiovascular (CV) risk factors in a British birth cohort from 1946. We studied four DNAm ages (AgeHannum, AgeHorvath, PhenoAge, and GrimAge) and their corresponding AgeAccel. Outcomes were the results from two publicly available ECG-based cardiac age scores: the Bayesian A-ECG-based heart age score of Lindow et al. 2022 and the deep neural network (DNN) ECG-based heart age score of Ribeiro et al. 2020. DNAm AgeAccel was also studied relative to results from two logistic regression-based A-ECG disease scores, one for left ventricular (LV) systolic dysfunction (LVSD), and one for LV electrical remodeling (LVER). Generalized linear models were used to explore the extent to which any associations between biological cardiometabolic risk factors (body mass index, hypertension, diabetes, high cholesterol, previous cardiovascular disease [CVD], and any CV risk factor) and the ECG-based outcomes are mediated by DNAm AgeAccel. We derived the total effects, average causal mediation effects (ACMEs), average direct effects (ADEs), and the proportion mediated [PM] with their 95% confidence intervals [CIs]. 498 participants (all 60-64 years) were included, with the youngest ECG heart age being 27 and the oldest 90. When exploring the associations between cardiometabolic risk factors and Bayesian A-ECG cardiac age, AgeAccelPheno appears to be a partial mediator, as ACME was 0.23 years [0.01, 0.52] p = 0.028 (i.e., PM≈18%) for diabetes, 0.34 [0.03, 0.74] p = 0.024 (i.e., PM≈15%) for high cholesterol, and 0.34 [0.03, 0.74] p = 0.024 (PM≈15%) for any CV risk factor. Similarly, AgeAccelGrim mediates ≈30% of the relationship between diabetes or high cholesterol and the DNN ECG-based heart age. When exploring the link between cardiometabolic risk factors and the A-ECG-based LVSD and LVER scores, it appears that AgeAccelPheno or AgeAccelGrim mediate 10-40% of these associations. By the age of 60, participants with accelerated DNA methylation appear to have older, weaker, and more electrically impaired hearts. We show that the harmful effects of CV risk factors on cardiac age and health, appear to be partially mediated by DNAm AgeAccelPheno and AgeAccelGrim. This highlights the need to further investigate the potential cardioprotective effects of selective DNA methyltransferases modulators.
Sections du résumé
BACKGROUND
DNA methylation (DNAm) age acceleration (AgeAccel) and cardiac age by 12-lead advanced electrocardiography (A-ECG) are promising biomarkers of biological and cardiac aging, respectively. We aimed to explore the relationships between DNAm age and A-ECG heart age and to understand the extent to which DNAm AgeAccel relates to cardiovascular (CV) risk factors in a British birth cohort from 1946.
RESULTS
We studied four DNAm ages (AgeHannum, AgeHorvath, PhenoAge, and GrimAge) and their corresponding AgeAccel. Outcomes were the results from two publicly available ECG-based cardiac age scores: the Bayesian A-ECG-based heart age score of Lindow et al. 2022 and the deep neural network (DNN) ECG-based heart age score of Ribeiro et al. 2020. DNAm AgeAccel was also studied relative to results from two logistic regression-based A-ECG disease scores, one for left ventricular (LV) systolic dysfunction (LVSD), and one for LV electrical remodeling (LVER). Generalized linear models were used to explore the extent to which any associations between biological cardiometabolic risk factors (body mass index, hypertension, diabetes, high cholesterol, previous cardiovascular disease [CVD], and any CV risk factor) and the ECG-based outcomes are mediated by DNAm AgeAccel. We derived the total effects, average causal mediation effects (ACMEs), average direct effects (ADEs), and the proportion mediated [PM] with their 95% confidence intervals [CIs]. 498 participants (all 60-64 years) were included, with the youngest ECG heart age being 27 and the oldest 90. When exploring the associations between cardiometabolic risk factors and Bayesian A-ECG cardiac age, AgeAccelPheno appears to be a partial mediator, as ACME was 0.23 years [0.01, 0.52] p = 0.028 (i.e., PM≈18%) for diabetes, 0.34 [0.03, 0.74] p = 0.024 (i.e., PM≈15%) for high cholesterol, and 0.34 [0.03, 0.74] p = 0.024 (PM≈15%) for any CV risk factor. Similarly, AgeAccelGrim mediates ≈30% of the relationship between diabetes or high cholesterol and the DNN ECG-based heart age. When exploring the link between cardiometabolic risk factors and the A-ECG-based LVSD and LVER scores, it appears that AgeAccelPheno or AgeAccelGrim mediate 10-40% of these associations.
CONCLUSION
By the age of 60, participants with accelerated DNA methylation appear to have older, weaker, and more electrically impaired hearts. We show that the harmful effects of CV risk factors on cardiac age and health, appear to be partially mediated by DNAm AgeAccelPheno and AgeAccelGrim. This highlights the need to further investigate the potential cardioprotective effects of selective DNA methyltransferases modulators.
Identifiants
pubmed: 37853450
doi: 10.1186/s13148-023-01576-9
pii: 10.1186/s13148-023-01576-9
pmc: PMC10583368
doi:
Substances chimiques
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
164Subventions
Organisme : Medical Research Council
ID : MC_UU_12019/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12019/5
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/20/2/34841
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ann Noninvasive Electrocardiol. 2014 Nov;19(6):534-42
pubmed: 25201032
J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):127-37
pubmed: 26130616
Circ Genom Precis Med. 2018 Mar;11(3):e001937
pubmed: 29555670
Sci Rep. 2020 Jul 1;10(1):10752
pubmed: 32612244
Genome Biol. 2016 Aug 11;17(1):171
pubmed: 27511193
Oncotarget. 2016 Nov 15;7(46):74510-74525
pubmed: 27793020
Int J Epidemiol. 2011 Feb;40(1):e1-9
pubmed: 21345808
PLoS One. 2017 Mar 30;12(3):e0171069
pubmed: 28358801
Ann N Y Acad Sci. 2001 Apr;928:1-21
pubmed: 11795501
Sci Rep. 2021 Mar 18;11(1):6272
pubmed: 33737563
Aging (Albany NY). 2022 Dec 14;14(23):9484-9549
pubmed: 36516495
Cell. 2016 Nov 17;167(5):1145-1149
pubmed: 27863232
Nucleic Acids Res. 2016 Feb 18;44(3):e20
pubmed: 26384415
Nat Commun. 2020 Apr 9;11(1):1760
pubmed: 32273514
Aging (Albany NY). 2018 Apr 18;10(4):573-591
pubmed: 29676998
Psychol Methods. 2010 Dec;15(4):309-34
pubmed: 20954780
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Nat Commun. 2021 Aug 25;12(1):5117
pubmed: 34433816
Clin Epigenetics. 2021 Oct 9;13(1):186
pubmed: 34627379
Sci Rep. 2022 Jul 27;12(1):12805
pubmed: 35896705
EBioMedicine. 2017 Jul;21:29-36
pubmed: 28396265
Mol Cell. 2013 Jan 24;49(2):359-367
pubmed: 23177740
Circ Cardiovasc Genet. 2016 Oct;9(5):436-447
pubmed: 27651444
Endocrinology. 2014 Dec;155(12):4925-38
pubmed: 25251587
Signal Transduct Target Ther. 2022 Jun 25;7(1):200
pubmed: 35752619
Metab Syndr Relat Disord. 2021 Jun;19(5):288-295
pubmed: 33656387
J Pers Med. 2014 Mar 07;4(1):65-78
pubmed: 25562143
Hypertension. 2022 Apr;79(4):761-772
pubmed: 34994206
J Gerontol A Biol Sci Med Sci. 2020 Feb 14;75(3):504-511
pubmed: 31630156
Circulation. 2014 Aug 12;130(7):565-72
pubmed: 24920721
Epidemiology. 2014 Sep;25(5):749-61
pubmed: 25000145
Sci Rep. 2022 Sep 6;12(1):15106
pubmed: 36068245
Aging (Albany NY). 2017 Feb 14;9(2):419-446
pubmed: 28198702
J Mol Cell Cardiol. 2018 Jul;120:53-63
pubmed: 29792884
Aging (Albany NY). 2019 Jan 21;11(2):303-327
pubmed: 30669119
Sci Rep. 2022 Jun 14;12(1):9840
pubmed: 35701514
Clin Epigenetics. 2021 Aug 9;13(1):155
pubmed: 34372922
Lancet. 2014 Jun 7;383(9933):1990-8
pubmed: 24630777
J Cardiovasc Dev Dis. 2015 May 13;2(2):93-107
pubmed: 29371514
J Electrocardiol. 2020 Jan - Feb;58:80-86
pubmed: 31785580
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):640-9
pubmed: 24249734
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
Expert Rev Cardiovasc Ther. 2016 Jul;14(7):855-69
pubmed: 27057779
Lancet Diabetes Endocrinol. 2015 Jul;3(7):526-534
pubmed: 26095709
Clin Epigenetics. 2014 Jul 29;6(1):14
pubmed: 25093045
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Mol Psychiatry. 2018 Feb;23(2):422-433
pubmed: 27843151
Exp Gerontol. 2018 May;105:4-9
pubmed: 29111233
Genome Biol. 2015 Dec 17;16:266
pubmed: 26673150
Future Cardiol. 2021 Nov;17(8):1335-1347
pubmed: 34008412
BMC Cardiovasc Disord. 2010 Jun 16;10:28
pubmed: 20565702